CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
20 hedge funds and large institutions have $11M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
1% less capital invested
Capital invested by funds: $11M → $11M (-$60.8K)
Holders
20
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$1.83M | |
| 2 | +$138K | |
| 3 | +$43.4K | |
| 4 |
CG
Colony Group
Boston,
Massachusetts
|
+$41.3K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$28.1K |
Top Sellers
| 1 | -$257K | |
| 2 | -$180K | |
| 3 | -$36.7K | |
| 4 |
RFWA
RPg Family Wealth Advisory
Burlington,
Massachusetts
|
-$34.2K |
| 5 |
Koshinski Asset Management
Decatur,
Illinois
|
-$13.5K |